Oppenheimer raised its price target on Viking Therapeutics to $116 from $46 and keeps an Outperform rating on the shares after the company reported positive topline results from the Phase 2 VENTURE trial of subQ VK2735, which the firm views as the best-case scenario. Given the promising results, Oppenheimer believes Viking has multiple options to explore additional dosing regimens and further optimize the safety/efficacy profile and improve patient experience.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VKTX:
- Viking Therapeutics Issues Regulation FD Disclosure Notice
- Viking Therapeutics sees 2024 adjusted EPS $4.25-$4.75 vs. $4.06 in 2023
- Viking Therapeutics reports Q4 core adjusted EPS $1.05, consensus (28c)
- Viking Therapeutics call volume above normal and directionally bullish
- Viking Therapeutics rumor highlighted again by Betaville blog
